September 26, 2021
Company Info
| Industry | Pharmaceuticals: Major |
|---|---|
| Sector | Health Technology |
| Employees | 94,066 |
| CEO | Ms. Emma N. Walmsley |
| Address | 980 Great West Road Brentford, Middlesex, GL TW8 9GS |
|---|---|
| Phone | 44.20.8047.5000 |
| Website | gsk.com |
GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Competitors
| Company Name | 3 Month %Change |
1 Year %Change |
|---|---|---|
| GlaxoSmithKline Plc | -3.30% | 2.70% |
| Pfizer Inc. | 12.12% | 29.69% |
| Thermo Fisher Scientific, Inc. | 23.10% | 45.83% |
| Novo Nordisk A/S | 22.51% | 47.50% |
| Danaher Corp. | 21.38% | 59.33% |
Statement Summary
as of 4:10 ET PM 09/23/2021| Total Assets (MRQ) | 106.4 B |
|---|---|
| Total Liabilities (MRQ) | 76.6 B |
| Shareholders’ Equity (MRQ) | 29.8 B |
| Total Revenue (Annual) | 11.3 B |
| Net Income (Annual) | 2.0 B |
Earnings And Estimates
as of 4:10 ET PM 09/23/2021
| Current Qtr EPS Estimate | 0.79 |
|---|---|
| Current FY EPS Estimate | 2.81 |
| Long Term EPS Growth Estimate | 9.72 |
| Next Expected Earnings Date | // |
GSK vs S&P 500
as of 09/23/2021| Relative To S&P 500 |
GSK | |
|---|---|---|
| 4 Weeks | n/a | n/a |
| 12 Weeks | n/a | n/a |
| YTD | n/a | n/a |
Earnings Surprises
as of 4:10 ET PM 09/23/2021| Fiscal Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 06/2021 | 0.54 | 0.78 | +43.98% |
| 03/2021 | 0.59 | 0.64 | +7.84% |
| 12/2020 | 0.63 | 0.64 | +0.42% |
| 09/2020 | 0.79 | 0.93 | +17.21% |
| 06/2020 | 0.50 | 0.50 | +0.28% |
| 03/2020 | 0.77 | 0.94 | +21.89% |
| 12/2019 | 0.67 | 0.64 | -3.57% |
| 09/2019 | 0.83 | 0.99 | +19.34% |
Financial Strength
as of 4:10 ET PM 09/23/2021| Pre-Tax Margin | 17.97 |
|---|---|
| Net Margin | -41.92 |
| Operating Margin | 22.38 |
| Return On Equity | 31.19 |
| Return On Assets | 5.62 |
| Inventory Turnover (TTM) | 1.72 |
| Sales Growth (MRQ) | 3.65 |
Ratios
as of 4:10 PM ET 09/23/2021| Price/Earnings (TTM) | 16.55 |
|---|---|
| Price/Book (MRQ) | 4.52 |
| Price/Cash Flow (TTM) | 13.22 |
| Book Value (MRQ) | 8.49 |
| Quick Ratio (MRQ) | 0.53 |
| Current Ratio (MRQ) | 0.82 |
| Total Debt/Equity (MRQ) | 1.66 |
Short Interest
as of 4:10 PM ET 09/24/2021| % Short - 0.65% | |
| % Remaining Float - 99.35% |
| Current | Last Month | |
|---|---|---|
| Short Interest Date | 08/31/2021 | 08/13/2021 |
| Short Interest Shares | 16,436,628 | 15,994,996 |
| Short Interest Ratio | 5.8 | 4.5 |
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00
0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00
0,0.00
Cash from
Activities
0,0.00
0,0.00
Cash from
Fin. Activities
0,0.00
0,0.00
TOTAL ASSETS |
TOTAL LIABILITIES |
TOTAL EQUITY |
|---|---|---|
Balance Sheet
| M Y | ||||
|---|---|---|---|---|
| ASSETS | ||||
| Cash And Equivalents | 0,0.00 | |||
| Receivables | 0,0.00 | |||
| Inventories | 0,0.00 | |||
| Other Current Assets | 0,0.00 | |||
| Total Current Assets | 0,0.00 | |||
| Property, Plant & Equipment, Gross | 0,0.00 | |||
| Accumulated Depreciation & Depletion | 0,0.00 | |||
| Property, Plant & Equipment, Net | 0,0.00 | |||
| Intangibles | 0,0.00 | |||
| Other Non-Current Assets | 0,0.00 | |||
| Total Non-Current Assets | 0,0.00 | |||
| TOTAL ASSETS | 0,0.00 | |||
| Liabilities & Shareholder Equity | ||||
| Accounts Payable | 0,0.00 | |||
| Short Term Debt | 0,0.00 | |||
| Total Current Liabilities | 0,0.00 | |||
| Long Term Debt | 0,0.00 | |||
| Deferred Income Taxes | 0,0.00 | |||
| Other Non-Current Liabilities | 0,0.00 | |||
| Minority Interest | 0,0.00 | |||
| Total Non-Current Liabilities | 0,0.00 | |||
| Preferred Stock Equity | 0,0.00 | |||
| Common Stock Equity | 0,0.00 | |||
| Common Par | 0,0.00 | |||
| Additional Paid In Capital | 0,0.00 | |||
| Cumulative Translation Adjustment | 0,0.00 | |||
| Retained Earnings | 0,0.00 | |||
| Treasury Stock | 0,0.00 | |||
| Other Equity Adjustments | 0,0.00 | |||
| Total Capitalization | 0,0.00 | |||
| TOTAL EQUITY | 0,0.00 | |||
| TOTAL LIABILITIES & STOCK EQUITY | 0,0.00 | |||
| Total Common Shares Outstanding | 0,0.00 | |||
| Preferred Shares | 0,0.00 | |||
| Treasury Shares | 0,0.00 | |||
| Basic Weighted Shares Outstanding | 0,0.00 | |||
| Diluted Weighted Shares Outstanding | 0,0.00 | |||
| Number Of Employees | 0,0.00 | |||
| Number Of Part-Time Employees | 0,0.00 | |||
TOTAL REVENUES |
EBT Excluding Unusual Items |
NET INCOME |
|---|---|---|
Income Statement
| M Y | |
|---|---|
| Sales | 0,0.00 |
| Cost Of Sales | 0,0.00 |
| Gross Operating Profit | 0,0.00 |
| Selling, General, And Administrative Expenses | 0,0.00 |
| Research & Development | 0,0.00 |
| Operating Income Before D & A (EBITDA) | 0,0.00 |
| Depreciation & Amortization | 0,0.00 |
| Interest Income | 0,0.00 |
| Other Income - Net | 0,0.00 |
| Special Income / Charges | 0,0.00 |
| Total Income Before Interest Expenses (EBIT) | 0,0.00 |
| Interest Expense | 0,0.00 |
| Pre-Tax Income | 0,0.00 |
| Income Taxes | 0,0.00 |
| Minority Interest | 0,0.00 |
| Net Income From Continuing Operations | 0,0.00 |
| Net Income From Discontinued Operations | 0,0.00 |
| Net Income From Total Operations | 0,0.00 |
| Extraordinary Income/Losses | 0,0.00 |
| Income From Cum. Effect Of Acct. Change | 0,0.00 |
| Income From Tax Loss Carryforward | 0,0.00 |
| Other Gains / Losses | 0,0.00 |
| Total Net Income | 0,0.00 |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
| Preferred Dividends | 0,0.00 |
| Net Income Available To Common | 0,0.00 |
| Basic EPS From Continuing Ops. | 0,0.00 |
| Basic EPS From Discontinued Ops. | 0,0.00 |
| Basic EPS From Total Operations | 0,0.00 |
| Basic EPS From Extraordinary Inc. | 0,0.00 |
| Basic EPS From Cum Effect Of Accounting Change | 0,0.00 |
| Basic EPS From Tax Loss Carryf'd. | 0,0.00 |
| Basic EPS From Other Gains (Losses) | 0,0.00 |
| Basic EPS, Total | 0,0.00 |
| Basic Normalized Net Income/Share | 0,0.00 |
| EPS From Continuing Ops. | 0,0.00 |
| EPS From Discontinued Ops | 0,0.00 |
| EPS From Total Ops. | 0,0.00 |
| EPS From Extraord. Inc. | 0,0.00 |
| EPS From Cum Effect of Accounting Change | 0,0.00 |
| EPS From Tax Loss Carfd. | 0,0.00 |
| EPS From Other Gains (L) | 0,0.00 |
| EPS, Total | 0,0.00 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
| Dividends Paid Per Share | 0,0.00 |
CASH FROM OPERATIONS |
CASH FROM INVESTING ACTIVITIES |
CASH FROM FINANCING ACTIVITIES |
|---|---|---|
Cash Flow Statement
| M Y | ||||
|---|---|---|---|---|
| Cash Flow From Operating Activities | ||||
| Net Income (Loss) | 0,0.00 | |||
| Operating Gains/Losses | 0,0.00 | |||
| Gross Operating Profit | 0,0.00 | |||
| (Increase) Decrease In Receivables | 0,0.00 | |||
| (Increase) Decrease In Inventories | 0,0.00 | |||
| (Increase) Decrease In Other Current Assets | 0,0.00 | |||
| (Decrease) Increase In Other Current Liabilities | 0,0.00 | |||
| (Increase) Decrease In Other Working Capital | 0,0.00 | |||
| Other Non-Cash Items | 0,0.00 | |||
| Net Cash From Continuing Operations | 0,0.00 | |||
| Net Cash From Discontinued Operations | 0,0.00 | |||
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 0,0.00 | |||
| Sale Of Property, Plant & Equipment | 0,0.00 | |||
| Cash Used For Investing Activities | ||||
| Sale Of Short-Term Investments | 0,0.00 | |||
| Purchases Of Property, Plant & Equipment | 0,0.00 | |||
| Acquisitions | 0,0.00 | |||
| Purchases Of Short-Term Investments | 0,0.00 | |||
| Other Cash From Investing Activities | 0,0.00 | |||
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 0,0.00 | |||
| Issuance Of Debt | 0,0.00 | |||
| Cash Used For Financing Activities | ||||
| Issuance Of Capital Stock | 0,0.00 | |||
| Repayment Of Long-Term Debt | 0,0.00 | |||
| Repurchase Of Capital Stock | 0,0.00 | |||
| Payment Of Cash Dividends | 0,0.00 | |||
| Other Financing Charges, Net | 0,0.00 | |||
| Net Cash From Financing Activities | 0,0.00 | |||
| Effect Of Exchange Rate Changes | 0,0.00 | |||
| Net Change In Cash & Cash Equivalents | 0,0.00 | |||
Earnings Estimates
as of 4:10 ET PM 09/23/2021| Current Qtr (09/2021) |
Next Qtr (12/2021) |
|
|---|---|---|
| Consensus Estimate | $0.79 | $0.61 |
| # of Estimates | 9 | 9 |
| High Estimate | $0.87 | $0.73 |
| Low Estimate | $0.69 | $0.46 |
| Year Ago EPS | $0.65 | $0.36 |
| Year Over Year Growth Estimate | 22.00% | 70.11% |
| Current Yr (12/2021) |
Next Yr (12/2022) |
|
|---|---|---|
| Consensus Estimate | $2.81 | $3.07 |
| # of Estimates | 21 | 21 |
| High Estimate | $2.95 | $3.30 |
| Low Estimate | $2.56 | $2.77 |
| Year Ago EPS | $3.15 | $2.81 |
| Year Over Year Growth Estimate | -10.84% | 9.17% |
| Current Qtr (09/2021) |
Next Qtr (12/2021) |
Current Year (12/2021) |
Next Year (12/2022) |
|
|---|---|---|---|---|
| Consensus Estimate | $0.79 | $0.61 | $2.81 | $3.07 |
| # of Estimates | 9 | 9 | 21 | 21 |
| High Estimate | $0.87 | $0.73 | $2.95 | $3.30 |
| Low Estimate | $0.69 | $0.46 | $2.56 | $2.77 |
| Year Ago EPS | $0.65 | $0.36 | $3.15 | $2.81 |
| Year Over Year Growth Estimate | 22.00% | 70.11% | -10.84% | 9.17% |
Insider Information Summary
as of 08/31/2021| % Insiders - 0.00% | |
| % Remaining Total Shares - 100.00% |
| Current | 1 Month | |
|---|---|---|
| Net Insider Transaction | 23.72 K | 22.28 K |
| Shares Bought | 23.72 K | 22.28 K |
| Shares Sold | 0.00 | 0.00 |
Insider Activity
| Transaction Date | Insider/Title | Transaction Type | Market Value | Shares | Average Price | Current Holdings | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
LATEST NEWS
23andMe Stock Soars on Outperform Initiation From Credit Suisse
Aug 17, 2021 10:15 AM EDT
Latest News
CureVac Stock Rises on Announcement of Positive Results for COVID Vaccines
Aug 16, 2021 9:01 AM EDT
Premarket Movers Monday: CureVac, UWM Holdings, Oatly, Sesen Bio
Aug 16, 2021 8:34 AM EDT
Alector Jumps on $2.2B GlaxoSmithKline Drug Development Deal
Jul 2, 2021 11:34 AM EDT
CureVac Slides After COVID-19 Vaccine Effectiveness Just 48%
Jul 1, 2021 8:00 AM EDT
5 Top Stock Gainers for Wednesday: Entera Bio, Under Armour, Xpeng
Jun 23, 2021 4:26 PM EDT
GlaxoSmithKline to Spin Off Consumer Division, Cut Dividend
Jun 23, 2021 8:53 AM EDT
CureVac Says COVID Vaccine Candidate Didn’t Meet Criteria
Jun 16, 2021 6:06 PM EDT
Mad Money Lightning Round: Marvell Technology, MicroVision, Oracle
May 20, 2021 7:30 AM EDT
Cramer's Mad Money Recap: GameStop, Advanced Micro Devices
May 19, 2021 9:05 PM EDT
Jim Cramer on Pfizer, Bank Earnings and DraftKings
Apr 16, 2021 10:09 AM EDT
Cramer's Mad Money Recap: UnitedHealth Group, Goldman Sachs
Apr 15, 2021 8:28 PM EDT
5 Top Stock Gainers for Thursday: Weingarten Realty, Dell, Nvidia
Apr 15, 2021 4:17 PM EDT
Inovio and CureVac Surge on Vaccine Candidate Results, J&J Pause
Apr 15, 2021 10:51 AM EDT
Recent Articles from TheStreet
Whole Foods Adds Service Fee for Amazon Prime Deliveries
Amazon's Whole Foods Market is ending free deliveries for Amazon Prime members, as it will add a $9.95 service fee beginning in October.
FedEx Is a Sell, Guilfoyle Says
Delivery giant recently missed estimates and has been late to raise prices.
Intel Starts Construction of Two Arizona Computer Chip Factories
Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.
Bret Jensen: Two Biotechs to Consider
Things are looking up for these drug companies as they make progress with the FDA
Guilfoyle: Oracle Not Likely to Rebound Soon
Database giant's troubles finding growth are limiting its upside for now.
Why Tim Collins Still Likes DocuSign
Digital signature company remains a good play on remote work changes
Jim Cramer Talks Macao With Wynn Resorts CEO
Matthew Maddox argues China's crackdown will lead to better regulation.
Electric Vehicle Checkpoint: Experts Say EV Revolution is Here
See the latest news for the top stocks in the electric vehicle space including Tesla, Ford, General Motors, Li Auto and more.
Tim Collins on How to Trade Nikola
Technical setups and short interest make much hated name volatile, and therefore interesting.
Jim Cramer: Gensler's Plate is Very Full
SEC Chairman is key player in efforts to rein in ceaseless financial engineering.
CLOSE
CLOSE
CLOSE
CLOSE